Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.

@article{Rovira2018TofacitinibHP,
  title={Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.},
  author={Jordi Rovira and Mar{\'i}a Jos{\'e} Ram{\'i}rez-Bajo and Elisenda Ba{\~n}{\'o}n-Maneus and Marta Lazo-Rodr{\'i}guez and Daniel Moya-Rull and Natalia Hierro-Garcia and Valeria Tubita and Gaston Julio Pi{\~n}eiro and Ignacio Revuelta and Pedro Ventura-Aguiar and David Cucchiari and Federico Oppenheimer and Merçe Brunet and Josep Mar{\'i}a Campistol and F. Diekmann},
  journal={Transplantation},
  year={2018},
  volume={102 7},
  pages={
          1075-1084
        }
}
BACKGROUND The progression from acute to chronic antibody-mediated rejection in kidney transplant recipients is usually not prevented by current therapeutic options. Here, we investigated whether the use of tofacitinib (TOFA), a Janus kinase 3 inhibitor, was capable of preventing the progression of allograft dysfunction in a Fisher-to-Lewis rat model of… CONTINUE READING